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BRIEF REPORT: CLINICAL SCIENCE
Enhanced Normalization of CD4/CD8 Ratio With Earlier
Antiretroviral Therapy at Primary HIV Infection
John Thornhill, MB, BCh, BAO,* Jamie Inshaw, BSc,† Pontiano Kaleebu, MBChB, PhD,‡
David Cooper, MD, DSc,§ Gita Ramjee, PhD,k Mauro Schechter, MD, PhD,¶ Giuseppe Tambussi, MD,#
Julie Fox, MBChB, MD,** Miriam Samuel, MBBS,** Jose M. Miro, MD, PhD,††
Jonathan Weber, FRCP,* Kholoud Porter, PhD,† and Sarah Fidler, MBBS, PhD,* On behalf of UK
Register of HIV Seroconverters and SPARTAC Trial Investigators
Background: Total CD4+ T-cell counts predict HIV disease
progression but do not necessarily reﬂect normalization of immune
function. CD4/CD8 ratio is a marker of immune dysfunction,
a prognostic indicator for non-AIDS mortality, and reﬂects viral
reservoir size. Despite antiretroviral therapy (ART), recovery of
CD4/CD8 ratio in chronic HIV infection is incomplete; we
hypothesize enhanced CD4/CD8 ratio recovery with earlier treat-
ment initiation in recently infected individuals.
Methods: CD4+ count and CD4/CD8 ratio were analyzed using data
from 2 cohorts: SPARTAC trial and the UK HIV Seroconverters
Cohort where primary HIV infection (PHI) was deﬁned as within 6
months from estimated date of infection. Using time-to-event methods
and Cox proportional hazard models, we examined the effect of CD4/
CD8 ratio at seroconversion on disease progression (CD4 ,350 cells
per cubic millimeter/ART initiation) and factors associated with time
from ART initiation to CD4/CD8 normalization (ratio .1.0).
Findings: Of 573 seroconverters, 482 (84%) had abnormal CD4/
CD8 ratios at HIV seroconversion. Individuals with higher CD4/
CD8 ratio at seroconversion were signiﬁcantly less likely to reach
the disease progression endpoint [adjusted hazard ratio (aHR) (95%
CI) = 0.52 (0.32 to 0.82), P = 0.005]. The longer the interval
between seroconversion and ART initiation [HR (95% CI) = 0.98 per
month increase (0.97, 0.99), P , 0.001], the less likely the CD4/
CD8 ratio normalization. ART initiation within 6 months from
seroconversion was signiﬁcantly more likely to normalize [HR (95%
CI) = 2.47 (1.67 to 3.67), P , 0.001] than those initiating later.
Interpretation: Most individuals presenting in PHI have abnormal
CD4/CD8 ratios. The sooner the ART is initiated in PHI, the greater
the probability of achieving normal CD4/CD8 ratio.
Key Words: primary HIV infection, seroconversion, acute HIV
infection, CD4/CD8 ratio, CD4:CD8, early antiretroviral therapy
(J Acquir Immune Deﬁc Syndr 2016;73:69–73)
BACKGROUND
Total CD4+ T-cell count is a validated surrogate marker
of disease progression for HIV/AIDS.1–3 Although the risk of
AIDS-related illness and opportunistic disease is signiﬁcantly
reduced once CD4 counts have recovered to levels.350 cells
per cubic millimeter,4–6 the risk of non-AIDS morbidity
persists.7 Despite recovery of total CD4+ T-cell counts with
antiretroviral therapy (ART), the CD4/CD8 ratio often fails to
normalize (deﬁned as .1) when ART is initiated in chronic
infection8 where reported normalization of CD4/CD8 ratio
ranges from 6% to 26.3%.3,9–11 A recent study from a large
Italian cohort reported a normalization rate of 29.4% despite 5
years of viral suppression on ART.12
Disruption of T-cell homeostasis by HIV induces CD4+
depletion and CD8+ T-cell expansion, resulting in an inverted
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CD4/CD8 ratio.13,14 Low CD4/CD8 ratio in individuals on
suppressive ART has been independently associated with
persistently elevated markers of T-cell activation8 and measures
of HIV viral reservoirs.15,16 In untreated HIV infection, CD4/
CD8 ratio inversely correlates with marker of T-cell activation
and exhaustion.17 In addition, low CD4/CD8 ratio independently
predicts all-cause mortality and non-AIDS–related events.17
CD4/CD8 T-cell ratio may therefore better predict immune
function than total CD4+ count alone17,18 and may contribute to
the observed START trial result, identifying a signiﬁcantly
enhanced clinical outcome for individuals starting ART at CD4
counts .500 cells per cubic millimeter.19 Enhanced normaliza-
tion of the CD4 T-cell count with ART initiated within 4 months
of seroconversion has recently been demonstrated.20 We
hypothesized that CD4/CD8 ratio recovery would also be
enhanced after immediate ART initiation initiated in primary
HIV infection (PHI). We examined the dynamics of immune
recovery by combining data from 2 cohorts of individuals with
well-estimated dates of HIV seroconversion.
METHODS
Cohort Descriptions
The 2 cohorts have been described previously.21,22
Brieﬂy, the UK HIV Seroconverters Cohort (UKHSC) is an
observational cohort of routine clinical data from individuals
with deﬁned HIV seroconversion dates collected between
1994 and 2014. Data were restricted to 2 clinical centers able
to provide CD8 T-cell data as these were not routinely
collected within UKHSC. SPARTAC (Short Pulse Anti-
Retroviral Therapy at Seroconversion) is an international
randomized clinical trial of 2 intervention arms in PHI, 12
weeks or 48 weeks of transient therapy vs. deferred treatment
(standard of care) across 8 countries.
Study Definitions
A normal CD4/CD8 T-cell ratio was deﬁned as $1.0.23
PHI was deﬁned as documented HIV infection within
a maximum of 6 months from a previous negative HIV
antibody test, p24 antigen positive in the absence of antibody,
or an “incident” RITA, recent incidence test algorithm test.21
Disease progression was deﬁned as CD4,350 cells per cubic
millimeter or long-term ART initiation.
Statistical Analysis
We examined the effect of CD4/CD8 ratio at PHI
(baseline) on time to disease progression endpoint using time-
to-event methods and Cox proportional hazards models, restrict-
ing to individuals with CD4+ .350 cells per cubic millimeter at
the time of PHI diagnosis. Baseline CD4/CD8 ratio was
included as a continuous variable and then as a categorical
variable (,0.5, 0.5–1.0, 1.0). The multivariate analyses were
adjusted for sex, age at PHI, risk group, ethnicity and enrollment
from an African site (as proxy for ethnicity), baseline CD4
count, and HIV-1 viral load. Follow-up was censored at date of
last recorded result. We checked for collinearity between
baseline CD4 and baseline CD4/CD8 ratio.
We then examined the effect of the interval between PHI
and ART initiation on time from ART initiation to normalized
CD4/CD8 ratio, again using time-to-event methods and Cox
proportional hazards models. All models were censored at the
earlier of a break in ART treatment (.7 days) or last visit before
April 24, 2014, whichever was earlier. Multivariate analyses
were adjusted for sex, risk group, ethnicity, ART regimen,
enrollment from an African site, year of seroconversion, interval
between baseline ratio and ART initiation, and both CD4+ count,
HIV-1 viral load, and age at ART initiation. For illustration
purposes, we used an arbitrary cutoff of 6 months to examine the
effect of a dichotomized duration of HIV infection at initiation of
ART, ART started ,6 months and ART initiated$6 months of
estimated date of seroconversion. The cutoff for a normal CD4/
CD8 ratio of 1.2 has been used by some groups3,9; a sensitivity
analysis was performed using this value. A further sensitivity
analysis was performed using a cutoff of 0.5.
FINDINGS
Overall, 573 individuals contributed CD4/CD8 data; of
whom, 482 (84%) had abnormal CD4/CD8 ratios (,1.0) at
baseline in PHI. Information was not available on Fiebig
staging although the vast majority of individuals were at stage
V or VI. Of 84, 155, and 334 individuals presenting with
CD4+ counts ,350, 350–500, and .500 cells per cubic
millimeter, 95% (n = 80), 91% (n = 141), and 78% (n = 261)
had abnormal CD4/CD8 ratios, respectively. The median
CD4/CD8 ratio (interquartile range) at baseline in PHI was
0.30 (0.21, 0.42) for those with CD4 count ,350 cells per
cubic millimeter, 0.46 (0.31, 0.66) for those with CD4 350–
500 cells per cubic millimeter, and 0.55 (0.35, 0.80) if CD4
was .500 cells per cubic millimeter.
Of 286 ART-naive individuals with baseline CD4 counts
.350 cells per cubic millimeter, the median time to the disease
progression endpoint was 1.51 (95% CI: 1.32 to 2.37) years.
Higher CD4/CD8 ratio at seroconversion was independently
associated with lower risk of endpoint [adjusted hazard ratio
(aHR) (95% CI) = 0.52 (0.32 to 0.82), P = 0.005], as was
higher baseline CD4 count [aHR (95% CI) = 0.79 per 100 cell
increase (0.71 to 0.86), P , 0.001].
Compared to individuals with CD4/CD8 ratio .1.0 at
PHI, those with lower ratios had greater risk of disease
progression [CD4/CD8 ratio,0.5: HR (95% CI) = 2.89 (1.74
to 4.79), P , 0.001; CD4/CD8 ratio .0.5 to #1.0: HR (95%
CI) = 1.97 (1.17 to 3.30), P = 0.010] (Fig. 1B).
We found strong evidence that those with longer time
between PHI and ART initiation were less likely to achieve
normal CD4/CD8 ratio [aHR (95% CI) = 0.98 per month
increase (0.97 to 0.99), P , 0.001] after adjusting for
confounding variables (including baseline HIV-1 Viral load
and CD4 count). The only other signiﬁcant covariate in the
model was baseline CD4+ cell count with normalization more
likely as count increased [HR = 1.12 (95% CI: 1.09 to 1.15)
per 50 cells per cubic millimeter increase, P, 0.001]. Results
from the sensitivity analysis (normal CD4/CD8 ratio .1.2
and .0.5) were qualitatively unchanged.
Of 468 individuals with abnormal CD4/CD8 ratio
initiating ART, 309 commenced ART within 6 months and
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159 initiated $6 months from seroconversion. Their baseline
characteristics are shown in Table 1. Overall median (inter-
quartile range) time to normalization of CD4/CD8 ratio was
715 (408, 988) days, 172 (117, 280) days for those in the ,6-
month group, and 1344 (1080, 1630) days for those in the
$6-month group. Those initiating ART within 6 months from
seroconversion were signiﬁcantly more likely to normalize
the CD4/CD8 ratio [HR (95% CI) = 2.47 (1.67 to 3.66), P ,
0.001], see Figure 1A. In addition, within 1 year from the date
of starting ART, 129/275 (46.9%) individuals in the ,6-
month group normalized the CD4/CD8 ratio, compared with
16/127 (12.6%) individuals in the $6-month group. A ﬁgure
illustrating the dynamics of the CD4 and CD8 T-cells counts
for each group is shown (see Fig. S2, Supplemental Digital
Content, http://links.lww.com/QAI/A810).
INTERPRETATION
Our ﬁndings demonstrate that ART initiated within 6
months from PHI markedly increases the likelihood of
normalization of the CD4/CD8 ratio compared with later
initiation of therapy, irrespective of baseline CD4 count. This
is in agreement with Serrano-Villar et al.24 In addition, we
found that the probability of achieving normalization of CD4/
CD8 ratio is increased for each month closer to seroconver-
sion ART is initiated. The normalization of CD4/CD8 ratio is
relatively rapid with almost half of the individuals achieving
this within 1 year of ART initiation. This ﬁnding is in contrast
to the reported normalization rates of CD4/CD8 ratio in
treated chronic HIV infection,3,10,11 where the chances of
normalization within 1 year of ART initiation remain low and
are comparable to those initiating ART $6 months in our
study. Higher rates of CD4/CD8 ratio normalization have
FIGURE 1. A, Kaplan–Meier plots of the
probability of time to normalization of the
CD4/CD8 ratio for those initiated on ART
within 6 months of estimated date of
seroconversion and those who deferred
ART to more than or equal to 6 months. B,
Kaplan–Meier plots of the probability of
initiating ART or CD4 count ,350
according to CD4/CD8 ratio group at
seroconversion: (1) ratio ,0.5, (2) $0.5
and #1.0, or (3) .1.0. This analysis used
data (n = 286) of those from the United
Kingdom Register of Seroconverters and
SPARTAC (including only those who were
not randomized to starting treatment).
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been reported in 2 studies of treated chronic infection, but
only following up to a median of 10 years on ART.9,25
Previously, international treatment guidelines have
varied on the CD4 count threshold that ART initiation is
recommended,26–28 with inconsistent guidelines on starting
ART in PHI. However, in light of the recent ﬁndings reported
by the START study,19 ART initiation regardless of CD4
T-cell count will be recommended by all international guide-
lines,29 which will include immediate ART initiation in PHI.
In this setting, PHI represents a speciﬁc scenario; despite
abnormal CD4/CD8 ratios in the majority of individuals at the
time of seroconversion, irrespective of initial CD4 count,
rapid ART initiation confers a signiﬁcantly enhanced prob-
ability of immunological recovery, which has not been
observed in later stage disease. Furthermore, given the high
rate of serious non-AIDS events at relatively high CD4 counts
seen in START, exploration of other biomarkers predictive of
disease progression such as CD4/CD8 ratio is warranted.
There are limitations to our study. As with all observa-
tional studies, it is not possible to adjust for unmeasured
confounders. For example, abnormal CD4/CD8 ratio has been
associated with Cytomegalovirus (CMV) infection seropositiv-
ity.30 As CMV data were not available from our cohorts, we
were unable to adjust for CMV infection. Furthermore,
abnormal CD4/CD8 is known to increase with age.31 Given
the relatively young, median age of 34 years, of our cohort, we
could not address the role of CD4/CD8 recovery in age groups
.50 years, who are known to progress faster.32 In addition, the
majority of those treated within 6 months received a boosted
protease inhibitor–based regimen, reﬂecting the SPARTAC trial
protocol of short-course ART, to avoid the risk of resistance to
nonnucleoside reverse transcriptase inhibitors on stopping owing
to their differential clearance.33,34 Those initiated beyond 6
months primarily received nonnucleoside reverse transcriptase
inhibitor–based regimens in keeping with local guidelines. We,
therefore, included ART class in the model and found no
evidence of an effect on CD4/CD8 ratio normalization.
CD4/CD8 ratio may have additional potential uses as
a biomarker in HIV cure research. Although there remains
a lack of consensus as to the optimal measurement of viral
reservoir,35 quantiﬁcation of reservoir size using total cellular
HIV-1 DNA remains the best clinical biomarker to predict
both disease progression and virological rebound among
individuals interrupting ART.15,36 Although HIV-1 DNA
was not measured for all individuals in this study, an analysis
of a subset of individuals from the SPARTAC trial found an
inverse correlation between HIV-1 DNA and CD4/CD8
ratio.37 As such, normalization of CD4/CD8 ratio may be
a future valuable biomarker, which better predicts those
individuals with a smaller HIV reservoir. This could inform
an algorithm to identify optimal candidates for cure inter-
ventions or treatment interruption. Furthermore, if CD4/CD8
ratio reﬂects HIV reservoir size, then our data support the
ﬁnding by other groups that treatment with ART at PHI may
limit HIV reservoir size.38
In conclusion, CD4/CD8 ratio normalization, albeit rare
when ART is started in chronic infection, is markedly
enhanced with ART initiation in PHI, with a greater beneﬁt
the sooner ART is started.
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